Abstract
The interferon-inducible, double-stranded RNA (dsRNA)-activated protein kinase, PKR, plays key roles in regulation of cell growth and differentiation, and has been postulated as a tumor suppressor. Downstream effectors of PKR include the translation initiation factor, eIF2α, and the transcription factor, NF-κB. We found elevated levels of PKR protein, dsRNA-dependent PKR autophosphorylation activity, and phosphorylated eIF2α in melanoma cells compared to nontransformed melanocytes in culture. Treatment with interferon-α2b further induced PKR expression and activity. Immunohistochemical analysis of primary melanomas demonstrated minimal PKR immunoreactivity, but melanoma lymph node metastases expressed a high level of PKR protein. Furthermore, analysis of colon cancer specimens revealed that transformation from normal mucosa to adenomas and carcinomas was coincident with an increase in PKR expression. These data do not support the concept of PKR as a classic tumor suppressor but instead suggest that PKR upregulation occurs at defined steps in cancer progression, probably as a cellular response to neoplasia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abraham N, Stojdl DF, Duncan PI, Methot N, Ishii T, Dube M, Vanderhyden BC, Atkins HL, Gray DA, McBurney MW, Koromilas AE, Brown EG, Sonenberg N, Bell JC . 1999 J. Biol. Chem. 274: 5953–5962
Barber GN . 2001 Cell Death Differ. 8: 113–126
Barber GN, Jagus R, Meurs EF, Hovanessian AG, Katze MG . 1995 J. Biol. Chem. 270: 17423–17428
Bonnet MC, Weil R, Dam E, Hovanessian AG, Meurs EF . 2000 Mol. Cell. Biol. 20: 4532–4542
Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ . 1976 Proc. Natl. Acad. Sci. USA 73: 3278–3282
Clemens MJ, Bommer UA . 1999 Int. J. Biochem. Cell Biol. 31: 1–23
Delhem N, Sabile A, Gajardo R, Podevin P, Abadie A, Blaton MA, Kremsdorf D, Beretta L, Brechot C . 2001 Oncogene 20: 5836–5845
Donze O, Jagus R, Koromilas AE, Hershey JW, Sonenberg N . 1995 EMBO J. 14: 3828–3834
Gil J, Alcami J, Esteban M . 2000 Oncogene 19: 1369–1378
Gil J, Esteban M . 2000 Apoptosis 5: 107–114
Gil J, Rullas J, Garcia MA, Alcami J, Esteban M . 2001 Oncogene 20: 385–394
Green SR, Mathews MB . 1992 Genes Dev. 6: 2478–2490
Haines III GK, Panos RJ, Bak PM, Brown T, Zielinski M, Leyland J, Radosevich JA . 1998 Tumour Biol. 19: 52–59
Haines GK, Becker S, Ghadge G, Kies M, Pelzer H, Radosevich JA . 1993a Arch. Otolaryngol. Head Neck Surg. 119: 1142–1147
Haines GK, Cajulis R, Hayden R, Duda R, Talamonti M, Radosevich JA . 1996 Tumour Biol. 17: 5–12
Haines GK, Ghadge G, Thimmappaya B, Radosevich JA . 1992 Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 62: 151–158
Haines GK, Ghadge GD, Becker S, Kies M, Pelzer H, Thimmappaya B, Radosevich JA . 1993b Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 63: 289–295
Ishii T, Kwon H, Hiscott J, Mosialos G, Koromilas AE . 2001 Oncogene 20: 1900–1912
Jagus R, Joshi B, Barber GN . 1999 Int. J. Biochem. Cell. Biol. 31: 123–138
Jaramillo M, Abraham N, Bell J . 1995 Cancer Invest. 13: 327–338
Kim S, Coit D . 1998 Cutaneous Oncology: Pathophysiology, Diagnosis, and Treatment Miller S and Maloney M (eds) Cambridge, MA: Blackwell Science, Inc pp 303–315
Kim SH, Forman AP, Mathews MB, Gunnery S . 2000 Oncogene 19: 3086–3094
Kinzler KW, Vogelstein B . 1996 Cell 87: 159–170
Kirkwood J, Strawderman M, Ernstoff M, Smith T, Borden E, Blum R . 1996 J. Clin. Oncol. 14: 7–17
Koromilas AE, Roy S, Barber GN, Katze MG, Sonenberg N . 1992 Science 257: 1685–1689
Laemmli UK . 1970 Nature 227: 680–685
Mathews MB, Pe'ery T . 2001 Trends Biochem. Sci. 26: 585–587
Meurs EF, Galabru J, Barber GN, Katze MG, Hovanessian AG . 1993 Proc. Natl. Acad. Sci. USA 90: 232–236
Offermann MK, Zimring J, Mellits KH, Hagan MK, Shaw R, Medford RM, Mathews MB, Goodbourn S, Jagus R . 1995 Eur. J. Biochem. 232: 28–36
Oldfield S, Jones BL, Tanton D, Proud CG . 1994 Eur. J. Biochem. 221: 399–410
Pataer A, Vorburger SA, Barber GN, Chada S, Mhashilkar AM, Zou-Yang H, Stewart AL, Balachandran S, Roth JA, Hunt KK, Swisher SG . 2002 Cancer Res. 62: 2239–2243
Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Aubock J, Fritsch P, Kerl H, Wolff K . 1998 J. Clin. Oncol. 16: 1425–1429
Proud CG . 1995 Trends Biochem. Sci. 20: 241–246
Raveh T, Hovanessian AG, Meurs EF, Sonenberg N, Kimchi A . 1996 J. Biol. Chem. 271: 25479–25484
Romano PR, Garcia-Barrio MT, Zhang X, Wang Q, Taylor DR, Zhang F, Herring C, Mathews MB, Qin J, Hinnebusch AG . 1998 Mol. Cell. Biol. 18: 2282–2297
Samuel CE . 2001 Clin. Microbiol. Rev. 14: 778–809 table of contents
Savinova O, Joshi B, Jagus R . 1999 Int. J. Biochem. Cell. Biol. 31: 175–189
Shang Y, Baumrucker CR, Green MH . 1998 J. Biol. Chem. 273: 30608–30613
Shimada A, Shiota G, Miyata H, Kamahora T, Kawasaki H, Shiraki K, Hino S, Terada T . 1998 Cancer Res. 58: 4434–4438
Sieber OM, Tomlinson IP, Lamlum H . 2000 Mol. Med. Today 6: 462–469
Singh C, Haines GK, Talamonti MS, Radosevich JA . 1995 Tumour Biol. 16: 281–289
Sudhakar A, Ramachandran A, Ghosh S, Hasnain SE, Kaufman RJ, Ramaiah KV . 2000 Biochemistry 39: 12929–12938
Terada T, Maeta H, Endo K, Ohta T . 2000a Hum. Pathol. 31: 817–821
Terada T, Ueyama J, Ukita Y, Ohta T . 2000b Liver 20: 450–457
Williams BR . 1999 Oncogene 18: 6112–6120
Williams BR . 2001 Sci. STKE 2001: RE2
Yang YL, Reis LF, Pavlovic J, Aguzzi A, Schafer R, Kumar A, Williams BR, Aguet M, Weissmann C . 1995 EMBO J. 14: 6095–6106
Zamanian-Daryoush M, Der SD, Williams BR . 1999 Oncogene 18: 315–326
Zamanian-Daryoush M, Mogensen TH, DiDonato JA, Williams BR . 2000 Mol. Cell. Biol. 20: 1278–1290
Zhou Y, Gobl A, Wang S, Jacobsen MB, Janson ET, Haines III GK, Radosevich JA, Oberg K . 1998 Eur. J. Cancer 34: 2046–2052
Acknowledgements
We wish to thank Gene Marquet for valuable technical assistance with the immunohistochemistry. This work was supported by grant AI34552 to MBM from the National Institute of Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, S., Gunnery, S., Choe, J. et al. Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR. Oncogene 21, 8741–8748 (2002). https://doi.org/10.1038/sj.onc.1205987
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205987
Keywords
This article is cited by
-
Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer
Oncogene (2021)
-
Vault RNAs: hidden gems in RNA and protein regulation
Cellular and Molecular Life Sciences (2021)
-
Therapeutic effects of the PKR inhibitor C16 suppressing tumor proliferation and angiogenesis in hepatocellular carcinoma in vitro and in vivo
Scientific Reports (2020)
-
NDRG2 contributes to cisplatin sensitivity through modulation of BAK-to-Mcl-1 ratio
Cell Death & Disease (2018)
-
Cell death/proliferation roles for nc886, a non-coding RNA, in the protein kinase R pathway in cholangiocarcinoma
Oncogene (2013)